With a market capitalization (market cap) of $1.09B — a measure of how much the company is worth — Replimune Group, Inc. ranks #2,463 among the 2,529 companies tracked, and 346th in Healthcare as of September 24, 2026. Shares trade at $12.96, down 3.79% on the day.
of 2,529 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation September 23, 2026. Ranking headline cap is the snapshot figure as of September 24, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Sep 23, 2026 | $1.26B | +40.10% | $12.96 |
| 2025 | Dec 31, 2025 | $896.06M | -8.16% | $9.72 |
| 2024 | Dec 31, 2024 | $975.63M | +73.65% | $12.11 |
| 2023 | Dec 29, 2023 | $561.82M | -64.30% | $8.43 |
Ranking figure $1.09B as of September 24, 2026.
Replimune Group, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $12.96 as of September 23, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.26B on September 23, 2026. See how the ranking works.
The ranking snapshot ($1.09B as of September 24, 2026) and the latest historical observation ($1.26B on September 23, 2026) come from different FMP datasets. This page does not force them to match.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2026) used a weighted-average 92,803,711 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2026 weighted-average shares would give about $1.2B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2026
FY 2026
Undefined when revenue is zero
FY 2026
Undefined when revenue is zero
FY 2026
FY 2026
FY 2026
FY 2026
Not in this snapshot
FY 2026 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.09T | -1.49% |
| #21 | Johnson & Johnson JNJ | $648.67B | -0.01% |
| #24 |
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2026.
Visit websiteAs of September 24, 2026, Replimune Group, Inc. (REPL) is worth $1.09B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2026, Replimune Group, Inc.’s book equity is about $166.16M. Market cap is the market value of the outstanding shares. As of September 24, 2026, its market cap is $1.09B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Replimune Group, Inc. ranks #2,463 among the 2,529 companies tracked on MarketCapLens. In Healthcare it ranks #346 of 359.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 |
|---|
| Dec 30, 2022 |
| $1.57B |
| +22.67% |
| $27.20 |
| 2021 | Dec 31, 2021 | $1.28B | — | $27.10 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2026
| $468.73B |
| +0.03% |
| #35 | Merck & Co., Inc. MRK | $365.81B | -1.86% |
| #40 | UnitedHealth Group Incorporated UNH | $337.18B | -0.45% |
| #49 | Novartis AG NVS | $271.25B | +1.01% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2460 | Carter's Inc. CRI | $1.1B | -3.53% |
| #2461 | Deluxe Corporation DLX | $1.09B | +0.29% |
| #2462 | Biglari Holdings Inc. BH | $1.09B | +0.19% |
| #2464 | MeiraGTx Holdings plc MGTX | $1.09B | -4.86% |
| #2465 | Metropolitan Bank Holding Corp. MCB | $1.09B | -0.71% |
| #2466 | Prospect Capital Corporation PSEC | $1.09B | -1.36% |
Replimune Group, Inc.’s ranking market cap of $1.09B comes from the same snapshot as the rest of this site, as of September 24, 2026. It is not share price multiplied by the FY 2026 weighted-average share count of 92,803,711. The historical market-cap series last observed $1.26B on September 23, 2026 — a different FMP dataset from the ranking snapshot, so the two figures can disagree.
Over the past year, Replimune Group, Inc.’s market cap is up 215.42%, using historical market-cap records rather than today’s share count applied to past prices.
Replimune Group, Inc. (REPL) shares trade at $12.96, down 3.79% on the day, as of September 24, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.